Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy

David Zahavi; Dalal AlDeghaither; Allison O'Connell; Louis M Weiner

doi:10.1093/abt/tby002

Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy

Antib Ther. 2018 Jun 24;1(1):7-12. doi: 10.1093/abt/tby002. eCollection 2018 Jun.

Authors

David Zahavi¹, Dalal AlDeghaither¹, Allison O'Connell¹, Louis M Weiner¹

Affiliation

¹ Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center,3800 Reservoir Rd NW, Washington, DC 20007, USA.

Abstract

The targeting of surface antigens expressed on tumor cells by monoclonal antibodies (mAbs) has revolutionized cancer therapeutics. One mechanism of action of antibody-based immunotherapy is the activation of immune effector cells to mediate antibody-dependent cell-mediated cytotoxicity (ADCC). This review will summarize the process of ADCC, its important role in the efficacy of mAb therapy, how to measure it, and finally future strategies for antibody design that can take advantage of it to improve clinical performance.

Keywords: ADCC; Fc glycosylation; FcγR; immunotherapy; monoclonal antibody.

Publication types

Review